Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,384,904
  • Shares Outstanding, K 146,759
  • Annual Sales, $ 9,891 M
  • Annual Income, $ 1,293 M
  • EBIT $ 2,377 M
  • EBITDA $ 3,451 M
  • 60-Month Beta 0.16
  • Price/Sales 2.63
  • Price/Cash Flow 7.82
  • Price/Book 1.42

Options Overview Details

View History
  • Implied Volatility 37.72% (+1.18%)
  • Historical Volatility 31.68%
  • IV Percentile 68%
  • IV Rank 43.63%
  • IV High 50.85% on 10/16/25
  • IV Low 27.55% on 01/07/26
  • Expected Move (DTE 3) 5.77 (3.27%)
  • Put/Call Vol Ratio 1.11
  • Today's Volume 1,951
  • Volume Avg (30-Day) 1,741
  • Put/Call OI Ratio 0.89
  • Today's Open Interest 50,177
  • Open Int (30-Day) 46,503
  • Expected Range 170.60 to 182.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 35 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $3.01
  • Number of Estimates 25
  • High Estimate $4.68
  • Low Estimate $1.66
  • Prior Year $3.02
  • Growth Rate Est. (year over year) -0.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
168.64 +4.58%
on 04/06/26
192.27 -8.27%
on 03/26/26
-5.18 (-2.86%)
since 03/13/26
3-Month
160.36 +9.98%
on 01/20/26
202.41 -12.87%
on 02/06/26
-1.93 (-1.09%)
since 01/13/26
52-Week
114.66 +53.82%
on 04/17/25
202.41 -12.87%
on 02/06/26
+61.20 (+53.13%)
since 04/11/25

Most Recent Stories

More News
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 35.05 (+2.10%)
BIIB : 176.37 (+1.96%)
1 S&P 500 Stock for Long-Term Investors and 2 We Ignore

1 S&P 500 Stock for Long-Term Investors and 2 We Ignore

TFC : 50.01 (+0.83%)
TDY : 655.99 (+1.59%)
BIIB : 176.37 (+1.96%)
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 35.05 (+2.10%)
BIIB : 176.37 (+1.96%)
1 Mid-Cap Stock with Promising Prospects and 2 We Brush Off

1 Mid-Cap Stock with Promising Prospects and 2 We Brush Off

WBS : 72.06 (+0.39%)
MDB : 236.14 (+4.51%)
BIIB : 176.37 (+1.96%)
1 Cash-Producing Stock for Long-Term Investors and 2 We Turn Down

1 Cash-Producing Stock for Long-Term Investors and 2 We Turn Down

SKY : 79.69 (+0.72%)
GDDY : 81.95 (+3.35%)
BIIB : 176.37 (+1.96%)
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

HIMS : 21.15 (+8.85%)
BMRN : 54.88 (+0.64%)
REGN : 746.46 (-0.32%)
MRNA : 50.68 (-0.55%)
BIIB : 176.37 (+1.96%)
Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Apellis Pharmaceuticals...

APLS : 40.84 (+0.12%)
BIIB : 176.37 (+1.96%)
Stocks Surge on Signs the US and Iran Seek to End War

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +2.91%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +2.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +3.43%. June E-mini...

ALK : 39.97 (+1.19%)
GOOGL : 321.31 (+1.28%)
AAPL : 259.20 (-0.49%)
SNDK : 952.50 (+11.83%)
ADI : 350.01 (-0.04%)
CNTA : 39.57 (+0.23%)
OXY : 58.06 (+0.16%)
TSLA : 352.42 (+0.99%)
STX : 513.28 (+2.02%)
WDC : 350.16 (+1.96%)
SPY : 686.10 (+0.98%)
META : 634.53 (+0.74%)
Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock?

Apellis Pharma stock more than doubled as Biogen announced a $5.6 billion acquisition. But for investors looking to jump into APLS shares now, the ship has already sailed.

APLS : 40.84 (+0.12%)
BIIB : 176.37 (+1.96%)
Stocks Climb on Hopes for an End to Iran War

The S&P 500 Index ($SPX ) (SPY ) today is up +1.02%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.67%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.10%. June E-mini S&P futures (ESM26...

GOOGL : 321.31 (+1.28%)
AMAT : 395.73 (-0.94%)
AAPL : 259.20 (-0.49%)
AVGO : 379.75 (+2.21%)
SNDK : 952.50 (+11.83%)
DHI : 144.33 (+1.18%)
BLDR : 87.53 (+2.61%)
CNTA : 39.57 (+0.23%)
$IUXX : 25,383.72 (+1.06%)
ASML : 1,500.20 (+1.48%)
ZNM26 : 111-125 (+0.14%)
MSFT : 384.37 (+3.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 183.93
2nd Resistance Point 180.36
1st Resistance Point 178.36
Last Price 176.37
1st Support Level 172.79
2nd Support Level 169.22
3rd Support Level 167.22

See More

52-Week High 202.41
Last Price 176.37
Fibonacci 61.8% 168.89
Fibonacci 50% 158.54
Fibonacci 38.2% 148.18
52-Week Low 114.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.